We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
Cambridge Investment Research Advisors
476
Cambridge Investment Research Advisors
Iowa
$12.7M +$1.11M +38,273 +10%
PWP
477
Private Wealth Partners
California
$12.6M -$708K -24,313 -5%
SCM
478
Sarissa Capital Management
Connecticut
$12.6M +$12.6M +432,140 New
PNC
479
Park National Corp
Ohio
$12.5M -$661K -22,725 -5%
BSPF
480
British Steel Pension Fund
United Kingdom
$12.5M -$806K -27,711 -6%
Creative Planning
481
Creative Planning
Kansas
$12.5M -$2.03M -69,722 -14%
FFIC
482
First Fiduciary Investment Counsel
Ohio
$12.4M -$353K -12,141 -3%
FPCM
483
Financial Partners Capital Management
New York
$12.4M -$73.9K -2,539 -0.6%
LCP
484
Lombardia Capital Partners
California
$12.3M -$124K -4,263 -1%
GWM
485
Greenwich Wealth Management
Connecticut
$12.3M -$10.4K -359 -0.1%
TSW
486
Thompson Siegel & Walmsley
Virginia
$12.2M -$4.7M -161,650 -28%
RP
487
Reinhart Partners
Wisconsin
$12.2M -$958K -32,917 -7%
WC
488
Whitnell & Co
Illinois
$12.2M -$30.7K -1,054 -0.3%
MHIC
489
Marble Harbor Investment Counsel
Massachusetts
$12.1M -$12.3K -422 -0.1%
CFC
490
Cincinnati Financial Corp
Ohio
$12.1M
GIM
491
Gyrus Investment Management
Ontario, Canada
$12M +$383K +13,175 +4%
BCM
492
Beddow Capital Management
Wyoming
$12M -$391K -13,423 -3%
KFC
493
Klingenstein Fields & Co
New York
$11.9M -$143K -4,913 -1%
GCC
494
Guardian Capital (Canada)
Ontario, Canada
$11.8M +$11.8M +405,667 New
SIM
495
Sentry Investment Management
Wisconsin
$11.7M -$4.53M -155,676 -28%
V
496
Veritable
Delaware
$11.6M +$2.88K +99 +0%
HIMC
497
Heritage Investors Management Corp
Maryland
$11.6M -$90.8K -3,119 -0.8%
RJT
498
Raymond James Trust
Florida
$11.6M +$876K +30,086 +8%
CIM
499
Calvert Investment Management
Maryland
$11.6M +$605K +20,774 +6%
CONA
500
Capital One National Association
New York
$11.5M -$362K -12,444 -3%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.